Format

Send to

Choose Destination
Pharmacotherapy. 1995 Jul-Aug;15(4):458-64.

The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease.

Author information

1
Department of General Internal Medicine, Rhode Island Hospital, Providence, USA.

Abstract

STUDY OBJECTIVE:

To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD).

DESIGN:

Randomized, double-blind, placebo-controlled trial.

SETTING:

Outpatient clinic.

PATIENTS:

Forty-four patients with documented premature CHD, defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years.

INTERVENTIONS:

Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks.

MEASUREMENTS AND MAIN RESULTS:

High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p < 0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p = 0.39) in a model that included treatment group assignment, and baseline Lp(a) levels.

CONCLUSIONS:

Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD.

PMID:
7479198
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center